Bioteque Corporation (4107) AI Stock Analysis

Bioteque Corporation

(TPEx:4107)

Select Model

Rating:78Outperform

Price Target:TWD 119.00▲(10.70% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is led by strong financial performance, particularly the low-leverage balance sheet and durable profitability. Attractive valuation adds support, while weak technical momentum and the established downtrend materially reduce the score.

Positive Factors

High ProfitabilitySustained high gross and net margins indicate durable pricing power and cost control across multiple years. This profitability provides internal funding for operations and investment, supports resilience through changing conditions, and creates a stronger base for maintaining earnings over the next several quarters.

Negative Factors

Uneven Revenue GrowthThe uneven revenue trajectory makes future earnings growth less predictable than the company’s strong margins would suggest. Periods of contraction can limit operating leverage and complicate planning, requiring sustained execution to convert the recent rebound into a consistent multi-year growth pattern.

Bioteque Corporation (4107) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 7.41B
Dividend Yield: 5.12%
Average Volume (3M): 45.42K
Price to Earnings (P/E): 12.3
Beta (1Y): 0.22
Revenue Growth: 10.16%
EPS Growth: 17.15%
Country: TW
Employees: 385
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Bioteque Corporation Business Overview & Revenue Model

Company Description

Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally. The company offers angiography catheter, balloon dilation catheter, guiding sheath, guide steel wire, y-type connector, multi-pipe...

Bioteque Corporation Financial Statement Overview

Summary

Strong profitability and margins, a very solid low-leverage balance sheet, and substantial equity support the score. Cash generation remains strong, although recent operating and free cash flow declines and moderating growth limit the upside.

Income Statement

88Very Positive

Balance Sheet

92Very Positive

Cash Flow

82Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.22B	2.14B	2.07B	1.94B	2.01B	1.83B
Gross Profit	998.57M	936.93M	905.08M	818.94M	844.54M	802.87M
EBITDA	906.39M	841.83M	850.60M	737.08M	759.13M	662.30M
Net Income	589.44M	539.18M	528.26M	452.55M	493.54M	431.26M
Balance Sheet
Total Assets	4.88B	4.66B	4.65B	4.62B	4.48B	3.86B
Cash, Cash Equivalents and Short-Term Investments	1.87B	1.67B	1.60B	1.57B	1.27B	1.31B
Total Debt	499.42M	597.51M	740.92M	894.74M	872.61M	473.83M
Total Liabilities	1.35B	1.05B	1.20B	1.43B	1.45B	1.06B
Stockholders Equity	3.53B	3.61B	3.44B	3.19B	3.03B	2.80B
Cash Flow
Free Cash Flow	591.42M	598.68M	604.19M	606.33M	-82.25M	-81.63M
Operating Cash Flow	697.95M	656.84M	702.62M	679.38M	644.58M	469.25M
Investing Cash Flow	-387.02M	-215.06M	-342.12M	-55.52M	-579.83M	-552.77M
Financing Cash Flow	-528.23M	-510.73M	-483.01M	-311.37M	68.77M	-232.65M

Bioteque Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4107 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4107	78Outperform	TWD 7.35B	12.29	―	5.12%	10.16%	17.15%
TW:4129	68Neutral	TWD 7.01B	12.73	―	6.19%	18.91%	10.75%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4169	54Neutral	TWD 7.93B	-291.25	―	0.27%	―	―
TW:4142	37Underperform	TWD 7.22B	-48.68	―	―	34.06%	―
TW:6499	33Underperform	TWD 7.33B	-16.44	―	―	69.62%	59.41%

* General Sector Average

Performance Comparison

TW:4107 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4107	Bioteque Corporation	107.50	-14.13	-11.62%
TW:4129	United Orthopedic Corporation	72.70	-42.36	-36.82%
TW:4142	Adimmune Corporation	16.60	-3.00	-15.31%
TW:4169	TCM Biotech International Corp.	116.50	-64.77	-35.73%
TW:6499	Medeon Biodesign, Inc.	73.80	-23.20	-23.92%
TW:6907	Artery Technology Corporation	123.50	74.84	153.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Bioteque Corporation AI Stock Analysis